Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Pharmacological and Therapeutic Properties of Cannabidiol for Epilepsy
Valentina Franco, Emilio Perucca
Drugs (2019) Vol. 79, Iss. 13, pp. 1435-1454
Closed Access | Times Cited: 147

Showing 1-25 of 147 citing articles:

The antimicrobial potential of cannabidiol
Mark A. T. Blaskovich, Angela M. Kavanagh, Alysha G. Elliott, et al.
Communications Biology (2021) Vol. 4, Iss. 1
Open Access | Times Cited: 222
Towards Better Delivery of Cannabidiol (CBD)
Sophie Millar, Ryan Maguire, Andrew Yates, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 9, pp. 219-219
Open Access | Times Cited: 172
Cannabinoids, the endocannabinoid system, and pain: a review of preclinical studies
David P. Finn, Simon Haroutounian, Andrea G. Hohmann, et al.
Pain (2021) Vol. 162, Iss. 1, pp. S5-S25
Open Access | Times Cited: 162
Cannabidiol inhibits Nav channels through two distinct binding sites
Jian Huang, Xiao Fan, Xueqin Jin, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 43
Therapeutic Strategies to Ameliorate Neuronal Damage in Epilepsy by Regulating Oxidative Stress, Mitochondrial Dysfunction, and Neuroinflammation
Sahithi Madireddy, Samskruthi Madireddy
Brain Sciences (2023) Vol. 13, Iss. 5, pp. 784-784
Open Access | Times Cited: 42
Critical Aspects Affecting Cannabidiol Oral Bioavailability and Metabolic Elimination, and Related Clinical Implications
Emilio Perucca, Meir Bialer
CNS Drugs (2020) Vol. 34, Iss. 8, pp. 795-800
Closed Access | Times Cited: 124
Cannabis sativa: Much more beyond Δ9-tetrahydrocannabinol
Patrícia Alves, Cristina Amaral, Natércia Teixeira, et al.
Pharmacological Research (2020) Vol. 157, pp. 104822-104822
Closed Access | Times Cited: 106
The Effects of Cannabidiol, a Non-Intoxicating Compound of Cannabis, on the Cardiovascular System in Health and Disease
Aleksandra Kicman, Marek Toczek
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 18, pp. 6740-6740
Open Access | Times Cited: 104
Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research
Valentina Franco, Meir Bialer, Emilio Perucca
Neuropharmacology (2021) Vol. 185, pp. 108442-108442
Closed Access | Times Cited: 57
Cannabidiol for the treatment of refractory epilepsy in children: a critical review of the literature
Gabriela Araujo Moreira, Roddie Moraes Neto, Ricardo Gullit Ribeiro, et al.
Revista Paulista de Pediatria (2022) Vol. 41
Open Access | Times Cited: 47
Cannabidiol activates neuronal Kv7 channels
Han-Xiong Bear Zhang, Laurel M. Heckman, Zachary Niday, et al.
eLife (2022) Vol. 11
Open Access | Times Cited: 40
Cannabidiol and Cannabigerol Exert Antimicrobial Activity without Compromising Skin Microbiota
Mariana Veiga, Manuela Amorim, Inês Pinto-Ribeiro, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2389-2389
Open Access | Times Cited: 31
Ligand activation mechanisms of human KCNQ2 channel
Demin Ma, Yueming Zheng, Xiaoxiao Li, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 22
Therapeutic applicability of cannabidiol and other phytocannabinoids in epilepsy, multiple sclerosis and Parkinson's disease and in comorbidity with psychiatric disorders
Maria de Fátima dos Santos Sampaio, Yara Bezerra de Paiva, Tuane Bazanella Sampaio, et al.
Basic & Clinical Pharmacology & Toxicology (2024) Vol. 134, Iss. 5, pp. 574-601
Open Access | Times Cited: 11
Plant antibacterials: The challenges and opportunities
Tomayo Berida, Yemi A. Adekunle, Hannah Dada-Adegbola, et al.
Heliyon (2024) Vol. 10, Iss. 10, pp. e31145-e31145
Open Access | Times Cited: 8
Cannabidiol y epilepsia: avances en su investigación como opción terapéutica
Cecilia Zavala‐Tecuapetla, Ana Canseco-Alba, Joaquín Manjarrez-Marmolejo, et al.
eNeurobiología (2025) Vol. 16, Iss. 40
Open Access | Times Cited: 1
Cannabis for Chronic Pain: Mechanistic Insights and Therapeutic Challenges
Carla Matos, Ana Teresa Pereira, Maria João Dias, et al.
Stresses (2025) Vol. 5, Iss. 1, pp. 7-7
Open Access | Times Cited: 1
<p>Cannabinoids in the Treatment of Epilepsy: Current Status and Future Prospects</p>
Alessandra Morano, Martina Fanella, Mariarita Albini, et al.
Neuropsychiatric Disease and Treatment (2020) Vol. Volume 16, pp. 381-396
Open Access | Times Cited: 66
Chronic Cannabidiol Administration Fails to Diminish Blood Pressure in Rats with Primary and Secondary Hypertension Despite Its Effects on Cardiac and Plasma Endocannabinoid System, Oxidative Stress and Lipid Metabolism
Patryk Remiszewski, Iwona Jarocka-Karpowicz, Michał Biernacki, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 4, pp. 1295-1295
Open Access | Times Cited: 54
Major Phytocannabinoids and Their Related Compounds: Should We Only Search for Drugs That Act on Cannabinoid Receptors?
Leontina Elena Filipiuc, Daniela Carmen Ababei, Teodora Alexa‐Stratulat, et al.
Pharmaceutics (2021) Vol. 13, Iss. 11, pp. 1823-1823
Open Access | Times Cited: 54
Phytocannabinoids in Neurological Diseases: Could They Restore a Physiological GABAergic Transmission?
Pierangelo Cifelli, Gabriele Ruffolo, Eleonora De Felice, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 3, pp. 723-723
Open Access | Times Cited: 53
The Interplay Between Liver First-Pass Effect and Lymphatic Absorption of Cannabidiol and Its Implications for Cannabidiol Oral Formulations
Valentina Franco, Pavel Gershkovich, Emilio Perucca, et al.
Clinical Pharmacokinetics (2020) Vol. 59, Iss. 12, pp. 1493-1500
Open Access | Times Cited: 52
Cannabidiol Inhibition of Murine Primary Nociceptors: Tight Binding to Slow Inactivated States of Nav1.8 Channels
Han-Xiong Bear Zhang, Bruce P. Bean
Journal of Neuroscience (2021) Vol. 41, Iss. 30, pp. 6371-6387
Open Access | Times Cited: 45
Cannabidiol for the treatment of autism spectrum disorder: hope or hype?
João Francisco Cordeiro Pedrazzi, Frederico Rogério Ferreira, Danyelle Silva-Amaral, et al.
Psychopharmacology (2022) Vol. 239, Iss. 9, pp. 2713-2734
Closed Access | Times Cited: 31
Beyond Pain Relief: A Review on Cannabidiol Potential in Medical Therapies
Mariana Veiga, João Azevedo‐Silva, João Carlos Fernandes
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 155-155
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top